Literature DB >> 21748415

Inhibition of spleen tyrosine kinase for rheumatoid arthritis.

Aarat M Patel1, Daniel Lupash, Douglas Chew, Marc C Levesque, Larry W Moreland.   

Abstract

Entities:  

Year:  2011        PMID： 21748415     DOI： 10.1007/s11926-011-0195-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  2 in total

1.  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

Authors:  Mark C Genovese; Arthur Kavanaugh; Michael E Weinblatt; Charles Peterfy; Julie DiCarlo; Michael L White; Maryann O'Brien; Elliott B Grossbard; Daniel B Magilavy
Journal:  Arthritis Rheum       Date:  2011-02

2.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Ruben Burgos-Vargas; Ara H Dikranian; Gabriel Medrano-Ramirez; Jorge L Morales-Torres; Frederick T Murphy; Theresa Kane Musser; Nicholas Straniero; Angela V Vicente-Gonzales; Elliott Grossbard
Journal:  Arthritis Rheum       Date:  2008-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.